Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia.

Autor: Vijenthira A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Department of Medicine, University of Toronto, Toronto, ON, Canada., Volpe VO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Sekar A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Santos Azevedo R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Mikhaleva M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Gibson CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Martindale SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Fardoun R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Tyekucheva S; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA., Ren Y; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA., Fernandes SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Knisbacher BA; The Mina and Everard Goodman Faculty of Life Sciences, Ramat Gan, Israel.; Broad Institute of MIT and Harvard, Cambridge, MA., Hahn CK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Getz G; Department of Medicine, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA.; Department of Pathology, Massachusetts General Hospital, Boston, MA.; Krantz Family Center for Cancer Research and Dept. of Pathology, Massachusetts General Hospital, Boston, MA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.; Broad Institute of MIT and Harvard, Cambridge, MA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.

Publikováno v: Blood advances [Blood Adv] 2024 Dec 10; Vol. 8 (23), pp. 5949-5956.

A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.

Autor: Gadi D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Griffith A; Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Tyekucheva S; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Wang Z; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Rai V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Vartanov A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Thrash E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Fernandes SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Lehmberg TZ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lee B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Martindale SP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Machado JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Odejide O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Arnason J; Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, USA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Lederer JA; Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. jennifer_brown@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. jennifer_brown@dfci.harvard.edu.

Publikováno v: Leukemia [Leukemia] 2022 Mar; Vol. 36 (3), pp. 723-732. Date of Electronic Publication: 2021 Nov 06.